Safety of mTOR inhibitors in breast cancer
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F16%3A33160433" target="_blank" >RIV/61989592:15110/16:33160433 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1080/14740338.2016.1192604" target="_blank" >http://dx.doi.org/10.1080/14740338.2016.1192604</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/14740338.2016.1192604" target="_blank" >10.1080/14740338.2016.1192604</a>
Alternative languages
Result language
angličtina
Original language name
Safety of mTOR inhibitors in breast cancer
Original language description
Introduction: Despite advances in the treatment of metastatic breast cancer, the lack of response or relapse/progression during the course of therapy continue to present a challenge towards deeper understanding of dysregulated signaling pathways in breast cancer. Consequently, there is an unmet medical need for the development of new agents to overcome the resistance to therapy and improve the treatment outcome. Areas covered: In this review, the mechanism of action and the role of intracellular PI3K/AKT/mTOR signaling pathway inhibition in breast cancer patients are described. Everolimus has been approved in combination with exemestane for the treatment of hormone-receptor-positive advanced breast cancer after failure of nonsteroidal aromatase inhibitor therapy. The aim of this paper is to focus on the safety and efficacy of mTOR inhibitors in the treatment of breast cancer. Current strategies of major adverse event management and prevention are delineated.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/NT13564" target="_blank" >NT13564: Predictive factors of pathologic response to neoadjuvant chemotherapy in patients with HER-2 positive or triple negative breast carcinoma</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Expert Opinion on Drug Safety
ISSN
1474-0338
e-ISSN
—
Volume of the periodical
15
Issue of the periodical within the volume
8
Country of publishing house
GB - UNITED KINGDOM
Number of pages
11
Pages from-to
1075-1085
UT code for WoS article
000381534600009
EID of the result in the Scopus database
—